Navigation Links
Potential new drug target to fight tuberculosis identified
Date:7/30/2008

e sought to do in this research," he says.

One of the study's innovations involved the examination of M. tuberculosis as it interacted with bone marrowderived macrophages during the infective process.

"That's a huge change from standard anti-infective research, which typically deals with the pathogen simply replicating in culture," explains Dr. Vandal. "In our experiments, we wanted to see if biochemical actors would emerge in the infective process that might be inoperative in the usual in vitro setting."

The team specifically focused on changes in the pH (acidity) of the phagosome -- a structure that macrophages use to consume and destroy pathogens, including bacteria.

"As part of this process, the phagosome becomes acidic, which is thought to contribute to its ability to break down and destroy the pathogen," Dr. Ehrt explains. "However, M. tuberculosis appears to survive the acidification process, keeping its own internal pH stable."

How does the bacteria do this, despite being surrounded by the more highly acidic phagosome? To find out, the team used a kind of genetic tweaking that effectively disabled M.tuberculosis' ability to produce a key protein lying at its membrane -- a protease (enzyme) called Rv3671c.

They then watched how the organism fared without it.

"What we observed was pretty amazing -- without functioning Rv3671c, the mutant bacterium was easily destroyed in a low-pH environment, both in culture and inside the more acidic environment of the macrophage," says Dr. Vandal. "This revealed a new point of vulnerability for the bacterium."

The experiment also broke new ground because the researchers were able to accurately gauge the bacterium's internal pH with the organism lying inside a host cell.

"The ability to make those kinds of measurements will expand research into this type of host-pathogen interaction," Dr. Nathan believes.

The next step
'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers tap into a new and potentially better source of platelets for transfusion
2. TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer
3. UC San Diego researchers identify potential new drug candidates to combat bird flu
4. New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
5. The good and the bad of a potential Alzheimers target
6. Stanford study: Bioenergy potential of reviving abandoned agricultural land
7. Indiana U scientists uncover potential key to better drugs to fight toxoplasmosis parasite
8. Scientists find potential protein biomarkers for growth hormone
9. New technology enhances therapeutic potential of cord blood stem cells
10. Potential therapy discovered for hypophosphatasia, a congenital form of rickets
11. Compound has potential for new class of AIDS drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... German . Infectious proteins known as prions ... disease (BSE). The culprits are "incorrectly folded" proteins that ... prion diseases are not yet fully understood. Why are ... headed by Beat Meier (ETH Zurich, Switzerland) and Raimon ...
... This release is available in French . ... the McGill University Health Centre (MUHC), McGill University and ... use of cannabinoids do not cause an increase in ... in some non-serious adverse events. Several drugs ...
... The Stowers Institute,s Rong Li Lab has discovered that a ... also have a role in the formation of cysts in ... most common life-threatening genetic diseases and has shown that ... mice. The discovery was published in the ...
Cached Biology News:Tracking prions 2Medicines derived from cannabis: a review of adverse events 2Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment 2
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... says the company is making good progress in evaluating the full range of ... tissue stem cells. Adult tissue stem cells perform the day-to-day renewal and repair ...
(Date:7/28/2015)... 2015  PDL BioPharma, Inc. (PDL, or the Company) ... will release its second quarter 2015 financial results for ... 5, 2015, after market close. PDL,s management will host ... p.m. Eastern Time to discuss the financial results.  A ... via the webcast link on the PDL website. ...
(Date:7/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/z54c4k/biomedical ) ... Refrigerators and Freezers Market - Global Industry Analysis, ... 2022" report to their offering. ... has been segmented based on applications: hospitals, research ... The others segment includes applications of biomedical refrigerators ...
(Date:7/28/2015)...  Moerae Matrix Inc. announced today the initiation ... MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 ... characterized by inflammation and fibrosis.  The study, conducted ... is a double-blind, two-way cross-over design lipopolysaccharide (LPS) ... of MMI-0100 when given via inhalation to healthy ...
Breaking Biology Technology:Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2
... EXEL ) announced today that that it will hold its,Third ... ET /,7:00 a.m. PT to 2:00 p.m. ET / 11:00 a.m. ... may be accessed in the Event Calendar,page under Investors at ... until 9:00 p.m. PT / 12:00,a.m. ET on January 4, 2008. ...
... MannKind,Corporation (Nasdaq: MNKD ), focused on discovering, ... that it,will present at the Piper Jaffray Healthcare Conference ... Pierre Hotel in New York, NY. Interested parties ... of the,presentation in the Investor Relations section of the ...
... LAKE, N.J., Nov. 20 Barr,Pharmaceuticals, Inc. (NYSE: ... Barr,Laboratories, Inc., has initiated a challenge of the ... 10mg, 15mg & 20mg. Focalin XR is manufactured ... Holdings Inc. Barr filed its Abbreviated New ...
Cached Biology Technology:Barr Confirms Patent Challenge of Focalin(R) XR 2Barr Confirms Patent Challenge of Focalin(R) XR 3
The improved design and new mechanical solutions of Finnpipette Focus Multichannel Plus improves accuracy and precision.In these low volume multichannel pipettes, the super blow-out function ensures ...
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
... Physical Form: buffered aqueous solution. ... galactose from complex carbohydrates and glycoproteins. It ... under conditions where the pH must be ... cells. Unit Definition: ...
Rabbit anti-CRSP1 (TRAP220), Polyclonal Antibody, Unconjugated Applications: Immunohistochemistry - 1:100 - 1:500...
Biology Products: